Related Experiment Videos
Management of infections caused by respiratory syncytial virus
Insights
This consensus document outlines management strategies for respiratory syncytial virus (RSV) infections. It recommends palivizumab prophylaxis for high-risk infants and specific treatments like ribavirin for severe cases and transplant patients.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pharmacology
Background:
- Respiratory Syncytial Virus (RSV) is a significant cause of respiratory illness in infants and young children.
- Effective management strategies are crucial for high-risk populations to prevent severe outcomes.
- This document provides a consensus-based approach to RSV management in Sweden.
Framework:
- Palivizumab prophylaxis is recommended for specific high-risk groups, including infants with chronic respiratory diseases and premature infants born before 26 weeks gestation.
- Ribavirin inhalation may be considered for high-risk infants with severe RSV infections.
- Combination therapy with ribavirin and intravenous polyclonal immunoglobulin is suggested for transplant recipients with RSV pneumonia.
Implementation:
- The guidelines are based on evidence and expert consensus from the Medical Products Agency and the Swedish Reference Group for Antiviral Therapy.
- Palivizumab is a humanized monoclonal IgG1 antibody preparation for prophylaxis.
- Ribavirin is an antiviral medication used for treatment.
Implications:
- These recommendations aim to standardize and improve the care of infants and children with RSV infections.
- The guidelines highlight the need for targeted prophylaxis and treatment in vulnerable populations.
- Further evidence is needed for the treatment of other patient groups not covered by these recommendations.
Abstract:
This is a consensus document compiled by the Medical Products Agency in Sweden and the Swedish Reference Group for Antiviral Therapy on management of respiratory syncytial virus (RSV) infections. Prophylaxis against RSV infections using palivizumab, a commercially available humanized monoclonal IgG1 antibody preparation, is recommended for children <2 y of age with chronic respiratory diseases requiring continuous treatment (oxygen and/or inhalations and/or steroids) during the previous 6 months and children <6 months old who were born before gestational week 26. Ribavirin inhalation treatment may be considered in high-risk infants with clinical symptoms indicating a serious course of an RSV infection. Treatment with ribavirin in combination with intravenous polyclonal immunoglobulin should be considered in patients who have received an allogenic stem cell transplantation or organ transplantation with >1 episode of rejection treatment and who have mild or moderate RSV pneumonia. Evidence-based documentation for treatment of other groups of patients is lacking.